Abstract 100P
Background
Rapid diagnostic services (RDS) are a two-week wait pathway for patients with non-specific symptoms (e.g., weight loss and fatigue), concerning of malignancy, that do not fulfil criteria for a site-specific cancer referral. Notoriously, patients without clear red flag symptoms have longer time to diagnosis and worse outcomes. RDS are being expanded across England to provide a new referral route for this cohort of patients to improve time to diagnosis and the patient journey. This study aimed to create a cancer risk stratification tool based on levels of standard serum biomarkers to help clinicians triage patients attending Guy’s RDC.
Methods
We analysed a panel of standard serum biomarkers assessed at referral for patients seen at Guy´s RDC between December 2016 and April 2022. Latent class analysis (LCA) was applied to investigate classes of individuals characterized based on their biomarker values (according to medical cut-offs), which were then examined as predictors of cancer using multivariate logistic regression. The abnormal biomarkers identified within LCA class with higher risk of cancer were used to create a scoring system, which was then developed into a cancer stratification tool.
Results
LCA identified four biomarker profiles: 1) normal values for all markers (51% of population); 2) abnormal values for haemoglobin, creatinine, and inflammatory markers (28%); 3) abnormal values for neutrophil to lymphocyte ratio, neutrophils, and inflammatory markers (12%); 4) abnormal values for multiple (n=10) markers (8%). Compared with class 1, class 4 had an increased risk of cancer (Odds ratio (OR) 6.33; 95% Confidence Interval (CI) 5.92-6.77). Based on the biomarkers identified in class 4 we created a score giving one point to each abnormal biomarker. A score of >=2 was associated with an increased risk of cancer (OR 3.09; 95%CI 2.91-3.27), as compared to a score of <2 (Area under the curve for test-training split: 0.68, C-index: 0.7).
Conclusions
Our innovative approach to triage patients with non-specific symptoms in the RDC for cancer diagnosis suggests that a combination of 10 standard biomarkers could be used to help facilitate a more efficient diagnosis of cancer when presenting with vague symptoms.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract